Latest News for: ataxia-telangiectasia

Edit

Quince Therapeutics Completes Enrollment in Pivotal Phase 3 NEAT Clinical Trial in Ataxia-Telangiectasia

Business Wire 16 Jul 2025
... to evaluate its lead asset, eDSP, for the treatment of the rare neurodegenerative disease Ataxia-Tel .
Edit

Quince Therapeutics Completes Enrollment in Pivotal Phase 3 NEAT Clinical Trial in Ataxia-Telangiectasia (Form 8-K) (Quince Therapeutics Inc)

Public Technologies 16 Jul 2025
Pivotal Phase 3 NEAT Clinical Trial in Ataxia-Telangiectasia ... its lead asset, eDSP, for the treatment of the rare neurodegenerative disease Ataxia-Telangiectasia (A-T) ... About Ataxia-Telangiectasia.
  • 1

Article Search

tools
×
×
×
×